Join Now! /

CardiaTec Biosciences Secures £1.4m to combat cardiovascular diseases using Artificial Intelligence

Startacus RSS

by Startacus Admin

CardiaTec's picture

Cambridge-based startup, CardiaTec Biosciences raises investment to support further development of its mission to develop the next generation of cardiovascular disease targets.

Great news for CardiaTec, an AI drug target discovery company specialising in cardiovascular disease, having just secured a £1.4m pre-seed investment led by Laidlaw Scholars Ventures and APEX Ventures.
Cardiovascular diseases have persisted as the world's leading global cause of death since the 1980s. Yet, despite the rising number of deaths, cardiovascular investment and therapeutic innovation are immensely dwarfed when compared to fields such as oncology and neurodegenerative diseases. New technologies must emerge to help close the gap.
/cardiac imageCardiaTec is developing a target discovery platform leveraging AI to make sense of large-scale multiomic cardiovascular data. As opposed to conventional singular omic analysis, CardiaTec’s proprietary platform unravels relationships that span across every level of biology, from gene variation, methylation and expression to their connection to proteomic and metabolomic functions to best understand disease development.     
The company was co-founded by Raphael Peralta (CEO), Thelma Zablocki (COO), and Dr. Namshik Han (CTO). Raphael and Thelma are graduates of the University of Cambridge MPhil in Bioscience Enterprise. Dr. Namshik Han is a world-leading academic in AI applications for target and drug discovery, and he holds positions at the University of Cambridge as Head of AI at the Milner Therapeutics Institute and Associate Faculty of the Cambridge Centre for AI in Medicine. 
Dr. Namshik Han commented, “Recent advances in artificial intelligence are generating novel ways to interpret multiomic data. I am excited to lead CardiaTec’s technology strategy to establish a new paradigm for understanding the pathophysiology of cardiovascular diseases.”
Raphael Peralta, CEO of CardiaTec, said, “Cardiovascular disease research has been subject to some very positive recent events, including the acquisition of MyoKardia and The Medicine Company. We strongly believe, after several decades of stagnated investment and innovation, cardiovascular disease is re-emerging with newfound interest, driven not only by the increasing requirements to fulfil the unmet need as it persists as the world-leading cause of death, but in the application of AI in being able to drive new and meaningful insights to help meet patients needs. Therefore, CardiaTec finds itself incredibly well placed to help drive innovation forwards within this space, now supported by a great syndicate of investors.”  
This raise marks the first investment of Laidlaw Scholars Ventures (LSV), a new Venture Capital fund established by the Laidlaw Foundation to invest in businesses led by Laidlaw Scholars. LSV and APEX Ventures are co-leading the £1.4m round with participation from Crista Galli Ventures, o2h ventures and Cambridge Enterprise.
Niall Santamaria, Chief Investment Officer of LSV, said, “We are delighted to support this exceptional team on their mission to improve patient outcomes by using AI for good. Despite the prevalence of cardiovascular ailments, there has been significant under-investment, so we believe these funds will provide CardiaTec with the opportunity to unearth treatments that make a real difference to patients.”
A startup that's most certainly worth keeping an eye on.

Subscribe to our newsletter

If you would like to receive our startup themed newsletter, full of the latest startup opportunities, events, news, stories, tips and advice, then sign up here.
Startacus RSS
Business DealsSubmit Your Startup
Win TicketsNetwork and Collaborate
Our Latest Features

Published on: 6th July 2022

If you would like to enable commenting via your Startacus account, please enable Disqus functionality in your Account Settings.

Create an Idea!View Other Ideas, Projects or Startups
Why not Sign Up?
Create Projects
Edit Projects
Self Interviews
Self Starter of the Year
Product Giveaways
Subscribe to our Newsletter
Check us out at our Google+ page!